Journal of The Academy of Clinical Microbiologists

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  26 (2024)
Volume  23 (2021)
Volume  22 (2020)
Volume  21 (2019)
Volume  20 (2018)
Volume  19 (2017)
Volume  18 (2016)
Volume  17 (2015)
Volume  16 (2014)
Volume  15 (2013)
Related articles

VOLUME 19 , ISSUE 2 ( July-December, 2017 ) > List of Articles

Original Article

Susceptibility of uropathogenic multidrug-resistant Escherichia coli to Fosfomycin

Deepak Kumar, Arghya Das, Manish Kumar Purbey, Nidhi Gupta, Gopal Nath

Keywords : Escherichia coli, Fosfomycin, multidrug-resistance

Citation Information : Kumar D, Das A, Purbey MK, Gupta N, Nath G. Susceptibility of uropathogenic multidrug-resistant Escherichia coli to Fosfomycin. 2017; 19 (2):101-104.

DOI: 10.4103/jacm.jacm_53_16

License: CC BY-NC 4.0

Published Online: 17-08-2024

Copyright Statement:  Copyright © 2017; Wolters Kluwer India Pvt. Ltd.


Abstract

CONTEXT: Escherichia coli is one of the most important causes of urinary tract infections (UTIs). Increased antibiotic resistance may limit the therapeutic options for the treatment of E. coli infections. Fosfomycin an orally dispensed antibiotic has shown promising in vitro activity against multidrug-resistant (MDR) urinary E. coli pathogen; however, current resistance data from India are scarce. AIM: The aim of this study is to evaluate the in vitro Fosfomycin activity against uropathogenic MDR E. coli. MATERIALS AND METHODS: A total of 150 previously confirmed MDR E. coli urinary isolates were included in this study. Susceptibility testing and result interpretation of isolates to Fosfomycin was performed by the disc diffusion method as per the Clinical and Laboratory Standards Institute M100-S25 recommendations. RESULTS: Fosfomycin appears to exhibit excellent in vitro activity against the MDR E. coli urinary isolates. The susceptibility for Nitrofurantoin was fair, whereas for Ampicillin, Ofloxacin, Norfloxacin, Cefazoline and Trimethoprim/Sulphamethoxazole was found poor. CONCLUSION: In view of the high in vitro susceptibility to Fosfomycin in this population and the lack of cross-resistance between Fosfomycin and other agents, Fosfomycin may be considered a useful reserve drug in the treatment of uncomplicated UTIs caused by MDR E. coli.

PDF Share
  1. Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: Results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011;70:507-11.
  2. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: A systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents 2009;34:111-20.
  3. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G, et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010;35:240-3.
  4. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010;65:2459-63.
  5. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011;15:e732-9.
  6. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: Use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069-77.
  7. Keating GM. Fosfomycin trometamol: A review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs 2013;73:1951-66.
  8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25. USA: Wayne, Pennsylvania 19087; 2015.
  9. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 2008;46:2605-12.
  10. Gupta K, Stamm WE. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int J Antimicrob Agents 2002;19:554-6.
  11. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ; EMERGEncy ID NET Study Group. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008;47:1150-8.
  12. Gobernado M, Valdés L, Alós JI, Garcia-Rey C, Dal-Ré R, García-de-Lomas J, et al. Quinolone resistance in female outpatient urinary tract isolates of Escherichia coli: Age-related differences. Rev Esp Quimioter 2007;20:206-10.
  13. Lobel B, Valot A, Cattoir V, Lemenand O, Gaillot O. Comparison of antimicrobial susceptibility of 1,217 Escherichia coli isolates from women with hospital and community-acquired urinary tract infections. Presse Med 2008;37:746-50.
  14. Kahlmeter G, ECO.SENS. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: The ECO.SENS project. J Antimicrob Chemother 2003;51:69-76.
  15. Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother 1999;43:137-40.
  16. Alós JI, Serrano MG, Gómez-Garcés JL, Perianes J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect 2005;11:199-203.
  17. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: Recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 2001;48 Suppl 1:87-102.
  18. Available from: http://www.medicines.org.uk/emc/medicine/32238#POSOLOGY. [Last accessed on 2017 Nov 09].
  19. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 2003;22 Suppl 2:79-83.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.